BusinessDrug Candidates in Retinitis Pigmentosa Therapeutics Pipeline to Develop More as Gene Therapy: P&S Market ResearchBy Nasdaq OMXMar 27, 2018, 9:39 AM UTC
BusinessGenSight Biologics Enrolls First Patient in Pivotal Phase III Program of GS010 in Leber’s Hereditary Optic NeuropathyBy Nasdaq OMXFeb 29, 2016, 12:00 PM UTC
